Latin America will receive vaccines against pneumococcus

• May 8, 2024

The pneumonia is the first cause of death of children under 5 years of age worldwide and despite being a predictable disease it kills more than AIDS, malaria and measles together.

It is not surprising that the first country of Latin America in developing the vaccine against pneumococcus bacteria , be Nicaragua , since this is one of the nations that has developed a better immune system, given that vaccination programs cover 98% of the children population , but to date did not have resources to buy vaccines that in developed countries, cost between 50 and 90 dollars.

"For the first time, a developing country will get a vaccine at the same time as a developed nation, and the chosen one will be Nicaragua, "a spokesperson for the Global Alliance for Vaccination and Immunization (GAVI Alliance); and will be the first developing country to obtain a new vaccine against the pneumococcal bacteria, principal cause of pneumonia , which kills more than 1.5 million children a year and causes one death every 20 seconds.

From next Sunday, December 12, 2010, this country will receive the new vaccinations against him pneumococcus , provided by GAVI Alliance, which includes several states, the World Bank, the World Health Organization, Unicef , the industry and private donors.

Currently, only two countries in the developing world, The Gambia and Rwanda, have introduced the pneumococcal vaccine thanks to a donation from the industry managed through GAVI, but it was an older version with less coverage.

The new vaccine to be introduced in Nicaragua has been produced especially for the needs and types of bacteria that threaten developing countries, and the novelty lies in the fact that the distribution will be sustainable over time.

In particular, the objective of this program is to vaccinate approximately 130 million children before 2015 and save the lives of some 700 thousand minors .

Sources: Metro

Video Medicine: BIO-Europe Spring® 2017: Sinergium provides gateway to Latin American vaccine and biologics markets (May 2024).